Boehringer to invest $42 million in potential Alzheimer’s treatment

Boehringer Ingelheim of Germany has announced plans to collaborate with the privately-held US firm, Vitae Pharmaceuticals Inc, to investigate beta-secretase inhibitors for the treatment of Alzheimer’s disease.